Eton Pharmaceuticals, Inc. (ETON) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oramed Pharmaceuticals, Inc.

Protalix Biotherapeutics, Inc.

Eton Pharmaceuticals, Inc.

Ocugen, Inc.

Nektar Therapeutics

Esperion Therapeutics, Inc.

Talaris Therapeutics, Inc.

Annexon, Inc.

Inovio Pharmaceuticals, Inc.

Reviva Pharmaceuticals Holdings, Inc.

Calidi Biotherapeutics, Inc.

Why is Eton Pharmaceuticals, Inc. ?

Poor Management Efficiency with a low ROE of 1.18%

The company has been able to generate a Return on Equity (avg) of 1.18% signifying low profitability per unit of shareholders funds

Negative results in Jun 25

INTEREST(HY) At USD 2.36 MM has Grown at 413.26%
PRE-TAX PROFIT(Q) At USD -2.46 MM has Fallen at -155.73%
NET PROFIT(Q) At USD -2.52 MM has Fallen at -156.66%

Risky - Negative Operating Profits

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 35.33%, its profits have fallen by -484%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Eton Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Eton Pharmaceuticals, Inc.

42.22%

5.70

61.82%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

125.72%

EBIT Growth (5y)

14.82%

EBIT to Interest (avg)

-6.66

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.52

Sales to Capital Employed (avg)

1.34

Tax Ratio

1.98%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.77%

ROCE (avg)

2.75%

ROE (avg)

1.18%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.47

EV to EBIT

-288.00

EV to EBITDA

464.26

EV to Capital Employed

12.51

EV to Sales

9.61

PEG Ratio

Dividend Yield

ROCE (Latest)

-4.35%

ROE (Latest)

-16.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 12.24 MM

NET PROFIT(HY)

Higher at USD -3.44 MM

NET SALES(Q)

Highest at USD 18.93 MM

RAW MATERIAL COST(Y)

Fallen by -1.64% (YoY

-18What is not working for the Company

INTEREST(HY)

At USD 2.36 MM has Grown at 413.26%

PRE-TAX PROFIT(Q)

At USD -2.46 MM has Fallen at -155.73%

NET PROFIT(Q)

At USD -2.52 MM has Fallen at -156.66%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.83 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.02 times

Here's what is working for Eton Pharmaceuticals, Inc.

Net Sales

Highest at USD 18.93 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

At USD 18.93 MM has Grown at 56.67%

over average net sales of the previous four periods of USD 12.08 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD 12.24 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by -1.64% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Eton Pharmaceuticals, Inc.

Interest

At USD 2.36 MM has Grown at 413.26%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -2.46 MM has Fallen at -155.73%

over average net sales of the previous four periods of USD -0.96 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -2.52 MM has Fallen at -156.66%

over average net sales of the previous four periods of USD -0.98 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Inventory Turnover Ratio

Lowest at 1.83 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 6.02 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio